A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
- Study ID
- NCT07392866
- Phase
- PHASE2/PHASE3
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Hepatocellular Carcinoma (HCC)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- SH006 — DRUG15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
- Bevacizumab — DRUG15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
- Oxaliplatin injection — DRUG85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
- Capecitabine — DRUG1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
- Regorafenib — DRUG160 mg orally once daily for 21 days continuous dosing followed by a 7-day break of each 28-day cycle
Study Details
To evaluate the efficacy and safety of the combination therapy of SH006 injection in the treatment of advanced hepatocellular carcinoma
Key Dates
- First listed
- Feb 6, 2026
- Start date
- Mar 1, 2026
- Status verified
- Feb 2026
- Primary completion
- Mar 1, 2030
- Completion
- Mar 1, 2030
Study Design
- Enrollment
- 120 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm 1 SH006 in combination with bevacizumab and chemotherapy
- Experimental: Arm 2 SH006 in combination with bevacizumab
- Experimental: Arm 3 SH006 in combination with chemotherapy
- Active Comparator: Arm 4 Regorafenib
Primary Outcome Measure
Progression-free Survival (PFS) (Phase II) [ Time Frame: Up to approximately 4 years ]
Central Contacts
- Jie Min86-15121121360
Related Studies
- FAST (Focused Abbreviated Screening Technique)-MRI StudyEnrolling By Invitation · Icahn School of Medicine at Mount Sinai · Los Angeles, California
- ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular CarcinomaPHASE1/PHASE2 · Recruiting · Eureka Therapeutics Inc. · Los Angeles, California
- Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid TumorsPHASE1 · Recruiting · Exelixis · Phoenix, Arizona
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)PHASE1/PHASE2 · Recruiting · GI Innovation, Inc. · Scottsdale, Arizona